Anti-CD20 monoclonal antibody that depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
YES
DIRECT
Binds CD20 and kills via immune effectors engaged by the antibody: ADCC by FcγR+ NK cells/macrophages, complement-dependent cytotoxicity (C1q activation), and possible direct apoptosis upon CD20 crosslinking.
A trispecific T-cell engager (multispecific antibody biologic) that binds CD3 on T cells and CD19/CD20 on B cells to redirect T-cell cytotoxicity against malignant B cells in relapsed/refractory B-cell non-Hodgkin lymphoma; administered with step-up then maintenance IV or SC dosing on 21-day cycles.
IgG-like trispecific T-cell engager that simultaneously binds CD3 on T cells and CD19/CD20 on B cells, redirecting and activating cytotoxic T cells to kill CD19/CD20-expressing malignant B cells and reducing antigen-escape by dual B-cell targeting.
NO
INDIRECT
The trispecific engager binds CD3 on T cells to activate and redirect them to CD19/CD20 on B cells; the activated T cells then kill CD19/CD20+ cells via perforin/granzyme cytotoxicity. CD3+ T cells themselves are not targeted for killing.
A trispecific T-cell engager (multispecific antibody biologic) that binds CD3 on T cells and CD19/CD20 on B cells to redirect T-cell cytotoxicity against malignant B cells in relapsed/refractory B-cell non-Hodgkin lymphoma; administered with step-up then maintenance IV or SC dosing on 21-day cycles.
IgG-like trispecific T-cell engager that simultaneously binds CD3 on T cells and CD19/CD20 on B cells, redirecting and activating cytotoxic T cells to kill CD19/CD20-expressing malignant B cells and reducing antigen-escape by dual B-cell targeting.
YES
DIRECT
Trispecific T‑cell engager binds CD3 on T cells and CD19 on target cells, forming an immune synapse that activates T cells to release perforin and granzymes, causing apoptosis/lysis of CD19+ cells.
Antibody-drug conjugate targeting a tumor-associated cell-surface antigen; internalizes and releases a cytotoxic payload (e.g., topoisomerase I or microtubule-targeting warhead) to kill cancer cells.
HER2-directed antibody-drug conjugate (trastuzumab rezetecan). The trastuzumab antibody binds HER2 on tumor cells, is internalized, and a cleavable linker releases a camptothecin-derived topoisomerase I inhibitor that stabilizes Topo I-DNA complexes, causing DNA strand breaks, blocking DNA replication, and inducing apoptosis in HER2-expressing cancer cells.
YES
DIRECT
HER2-targeted ADC binds HER2, is internalized, and releases a camptothecin topoisomerase I inhibitor that causes DNA strand breaks, blocks replication, and induces apoptosis in HER2-expressing cells.
A trispecific T-cell engager (multispecific antibody biologic) that binds CD3 on T cells and CD19/CD20 on B cells to redirect T-cell cytotoxicity against malignant B cells in relapsed/refractory B-cell non-Hodgkin lymphoma; administered with step-up then maintenance IV or SC dosing on 21-day cycles.
IgG-like trispecific T-cell engager that simultaneously binds CD3 on T cells and CD19/CD20 on B cells, redirecting and activating cytotoxic T cells to kill CD19/CD20-expressing malignant B cells and reducing antigen-escape by dual B-cell targeting.
YES
DIRECT
Trispecific T-cell engager bridges CD3 on T cells to CD20 on B cells, activating T-cell cytotoxicity (perforin/granzyme- and Fas/FasL-mediated killing) against CD20-expressing cells.